Abstract:The endothelium represents an important source of, and a target for, inflammation in sepsis. Angiogenic factors and their receptors, including vascular endothelial growth factor (VEGF)/VEGF receptor and the angiopoietin/Tie2 signaling pathways, have recently received great attention in critically ill patients, including those with sepsis [1-3], because of their pivotal roles in both angiogenesis and microvascular permeability. VEGF, as the most potent proangiogenic factor, has already been identified as an important target for cancer therapy. Disassembly of an intact endothelial cell junction is necessary for the angiogenesis process. The endothelial barrier-breaking properties are indeed an important part of the VEGF role in the regulation of angiogenesis. However, a high dose or prolonged duration of VEGF may lead to excessive barrier-breaking effects. The favorable results observed with the only US Food and Drug Administration-approved anti-VEGF agent, bevacizumab, by Jeong and colleagues [4] are likely to provide potential advances for future therapeutic opportunities in sepsis. On the contrary, VEGF shows endothelial survival signals, and suppression of VEGF signaling inhibits endothelial survival and increases apoptosis, which in turn may contribute to the development of sepsis-induced organ dysfunction [5]. Furthermore, other than an independent function on endothelial cells, VEGF plays an important role in mobilizing endothelial progenitor cells under pathologic conditions such as cancer and sepsis. While the decrease of circulating endothelial progenitor cells (cEPCs) after anti-VEGF treatment is beneficial in cancer, this may not be so in sepsis. The endothelium is a chief target of sepsis-induced events, and clinical outcome in septic patients is largely dependent on the ability to reconstitute damaged endothelium. Indeed, several studies have observed an increase in cEPC numbers in septic patients and a correlation between cEPC concentration and survival. The increased number of cEPCs in sepsis might therefore be a consequence of the body’s attempt to limit vascular damage by inducing endogenous endothelial repair mechanisms. The dramatic decrease of cEPCs accompanied by anti-VEGF treatment may impair endothelial repair capacity and bring unfavorable effects in sepsis. The angiogenic factors and their soluble receptors therefore do have a complex role and seemingly play both good and bad roles during sepsis development and therapy. A certain level of VEGF is necessary for normalizing endothelial function, and abnormally high or low levels of VEGF might shift its role from endothelial protective to endothelial barrier disruptive. This view can also provide additional possible explanations for why Jeong and colleagues’ study suggests that a high dose of bevacizumab may have deleterious effects in an experimental sepsis model. Future studies on the dynamic change of the angiogenic factors, their soluble receptors and cEPC counts during and after each therapy, as well as the context-dependent role of them, may provide background data for using these angiogenic factors and their soluble receptors as therapeutic targets for sepsis treatment in clinical practice.

Endothelial microparticles activate endothelial cells to facilitate the inflammatory response.

Proteomic analysis of TNF-α-activated endothelial cells and endothelial microparticles.

M1 Macrophages Increase Endothelial Permeability and Enhance P38 Phosphorylation Via PPAR-γ/CXCL13-CXCR5 in Sepsis.

[Studies on the Cell Markers of Endothelial Function in Sepsis].

Oxidized Low-Density Lipoprotein-Induced Microparticles Promote Endothelial Monocyte Adhesion Via Intercellular Adhesion Molecule 1.

Sirt6 Mrna-Incorporated Endothelial Microparticles (emps) Attenuates DM Patient-Derived EMP-induced Endothelial Dysfunction

Endothelial Microparticles and Research Advances of Sepsis

Endothelial Microparticles Induced by Cyclic Stretch Activate Src and Modulate Cell Apoptosis.

Sphingosine 1-Phosphate Receptor-3 Enhances Pro-Inflammatory Activity in Human Monocytes (P1384)

Endothelial Immunity Trained by Coronavirus Infections, DAMP Stimulations and Regulated by Anti-Oxidant NRF2 May Contribute to Inflammations, Myelopoiesis, COVID-19 Cytokine Storms and Thromboembolism

Endothelial Cell Dysfunction Due to Molecules Secreted by Macrophages in Sepsis

Bacterial lipopolysaccharide-induced endothelial activation and dysfunction: a new predictive and therapeutic paradigm for sepsis

Endothelial microparticles: A mechanosensitive regulator of vascular homeostasis and injury under shear stress

Endothelial exosomes work as a functional mediator to activate macrophages

IMPLICATION OF TOLL-LIKE RECEPTOR AND TUMOR NECROSIS FACTOR α SIGNALING IN SEPTIC SHOCK

Endothelial Cells and Sepsis

Endothelial Responses in Sepsis

Endothelial cells microparticle-associated protein disulfide isomerase promotes platelet activation in metabolic syndrome

The association of endothelial cell signaling, severity of illness, and organ dysfunction in sepsis

Circulating extracellular vesicles are associated with the clinical outcomes of sepsis

The Angiogenic Factors and Their Soluble Receptors in Sepsis: Friend, Foe, Orboth?